Russian Heart Failure Journal 2008year ‘‘One step forward, two steps on the spot’’: results of key clinical trials on patients with CHF published in 2007


To access this material please log in or register

Register Authorize
2008/

‘‘One step forward, two steps on the spot’’: results of key clinical trials on patients with CHF published in 2007

Gilyarevsky S. R.

Keywords:

DOI:

    1.    Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med. 2007;357 (22):2248–2261.
    2.    Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 2002;39 (10):1567–1573.
    3.    Böhm M, Hjalmarson A, Kjekshus J et al. Heart failure and statins – why do we need a clinical trial? Z Kardiol. 2005;94 (4):223–230.
    4.    Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005;7 (6):1059–1069.
    5.    Cleland JG, Loh H, Windram J et al. Threats, opportunities, and statins in the modern management of heart failure. Eur Heart J. 2006;27 (6):641–643.
    6.    Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8 (4):216–224.
    7.    Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42 (11):1933–1940.
    8.    Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356 (9233):930–933.
    9.    Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49 (23):2231–2237.
    10.    Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363 (9412):892–894.
    11.    Uretsky BF, Thygesen K, Armstrong PW et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102 (6):611–616.
    12.    Orn S, Cleland JG, Romo M et al. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med. 2005;118 (7):752–758.
    13.    Krum H, Latini R, Maggioni AP et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119 (1):48–53.
    14.    Go AS, Lee WY, Yang J et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296 (17):2105–2111.
    15.    van der Harst P, Voors AA, van Gilst WH et al. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med. 2006;3 (8): e333.
    16.    Martin J. H, Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007;113:119–127.
    17.    Krum H, Ashton E, Reid C et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail. 2007;13 (1):1–7.
    18.    Collins R, Armitage J, Parish S et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363 (9411):757–767.
    19.    Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360 (9346):1623–1630.
    20.    Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344 (8934):1383–1389.
    21.    Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335 (14):1001–1009.
    22.    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. 1: N Engl J Med. 1998;339 (19):1349–1357.
    23.    Tavazzi L, Tognoni G, Franzosi MG et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6 (5):635–641.
    24.    Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure. The EVEREST Clinical Status Trials. JAMA. 2007;297 (12):1319–1331.
    25.    Gheorghiade M, Konstam MA, Burnett JC Jr et al. Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure. The EVEREST Clinical Status Trials. JAMA. 2007;297 (12):1332–1343.
    26.    Mochizuki S, Dahlöf B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369 (9571):1431–1439.
    27.    Kubo M, Kiyohara Y, Kato I et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke. 2003;34 (10):2349–2354.
    28.    Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551–557.
    29.    Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol. 2001;87 (8A):3C-9C.
    30.    Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52 (1):11–34.
    31.    Suzuki K, Souda S, Ikarashi T et al. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract. 2002;57 (3):179–183.
    32.    Kasama S, Toyama T, Kumakura H et al. Addition of valsartan to an angiotensin converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med. 2003;44 (6):884–890.
    33.    Munakata M, Nagasaki A, Nunokawa T et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens. 2004;17 (11 Pt 1):1050–1055.
    34.    Kawano H, Toda G, Nakamizo R et al. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J. 2005;69 (10):1244–1248.
    35.    Suzuki H, Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res. 2005;28 (4):307–14.
    36.    Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl. 2005;23 (1): S9–17.
    37.    Munakata M, Nagasaki A, Nunokawa T et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens. 2004;17 (11 Pt 1):1050–1055.
    38.    Yasunari K, Maeda K, Watanabe T et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004;43 (11):2116–2123.
    39.    Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363 (9426):2022–2031.
    40.    Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet. 2002;359 (9311):995‑1003.
    41.    Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366 (9496):1545–1553.
    42.    Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21 (6):1055–1076.
    43.    Kimura Y, Takishita S, Muratani H et al. Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. J Hypertens. 2003;21 (6):1055–1076.
    44.    Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121 (4 Pt 1):1244–1263.
    45.    Sackett DL, Straus SE, Richardson WS et al. Evidence-Based Medicine: How to Practice and Teach EBM. 2nd ed. Edinburgh, United Kingdom: Churchill Livingstone, 2000:173–177.

To access this material please log in or register

Register Authorize
Ru En